Research recommendations coming out of this guidance What is the clinical and cost-effectiveness of regular 'fixed-dose' inhaled corticosteroid (ICS) regimens (using SABA [short-acting beta2 agonist] as a reliever) compared with 'as-needed' strategies (for example ICS/formoterol) as the initial standard treatment for asthma in children aged 5 to 11 years? What is the best step-up treatment for people whose asthma is not controlled on a combination inhaler of ICS plus formoterol used as needed? What is the cost-effectiveness and feasibility of the proposed BTS/NICE/SIGN diagnostic pathways for asthma in children and young people aged 5 and over and in adults aged 17 and over? Can digital inhaler monitors cost-effectively improve adherence to preventer inhalers for people with asthma? Does this improve asthma control and who would benefit most from this intervention?
What is the clinical and cost-effectiveness of regular 'fixed-dose' inhaled corticosteroid (ICS) regimens (using SABA [short-acting beta2 agonist] as a reliever) compared with 'as-needed' strategies (for example ICS/formoterol) as the initial standard treatment for asthma in children aged 5 to 11 years?
What is the best step-up treatment for people whose asthma is not controlled on a combination inhaler of ICS plus formoterol used as needed?
What is the cost-effectiveness and feasibility of the proposed BTS/NICE/SIGN diagnostic pathways for asthma in children and young people aged 5 and over and in adults aged 17 and over?
Can digital inhaler monitors cost-effectively improve adherence to preventer inhalers for people with asthma? Does this improve asthma control and who would benefit most from this intervention?